|
US618965A
(en)
*
|
|
1899-02-07 |
|
Filter |
|
US2228904A
(en)
|
1939-05-10 |
1941-01-14 |
Bjorkman Hugo Leonard |
Wrench
|
|
WO1981001145A1
(en)
|
1979-10-18 |
1981-04-30 |
Univ Illinois |
Hydrolytic enzyme-activatible pro-drugs
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
AU595623B2
(en)
|
1986-05-29 |
1990-04-05 |
Ilexus Pty Ltd |
Fc receptor for immunoglobulin
|
|
GB8705477D0
(en)
|
1987-03-09 |
1987-04-15 |
Carlton Med Prod |
Drug delivery systems
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
NZ226414A
(en)
|
1987-10-02 |
1992-07-28 |
Genentech Inc |
Cd4 peptide adhesion variants and their preparation and use
|
|
US5576184A
(en)
|
1988-09-06 |
1996-11-19 |
Xoma Corporation |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
|
US5681566A
(en)
|
1988-10-24 |
1997-10-28 |
3I Research Exploitation Limited |
Antibody conjugates with two or more covalently linked FC regions
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US20030229208A1
(en)
|
1988-12-28 |
2003-12-11 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
JP3051411B2
(ja)
|
1989-03-14 |
2000-06-12 |
持田製薬株式会社 |
新規ｄｎａならびにそれを含有する発現プラスミド
|
|
US5266491A
(en)
|
1989-03-14 |
1993-11-30 |
Mochida Pharmaceutical Co., Ltd. |
DNA fragment and expression plasmid containing the DNA fragment
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
JPH04505709A
(ja)
|
1989-11-07 |
1992-10-08 |
ブリストル―マイアーズ スクイブ カンパニー |
オリゴマー免疫グロブリン
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
AU7566991A
(en)
|
1990-03-14 |
1991-10-10 |
Biomembrane Institute, The |
Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
|
|
WO1991019515A1
(en)
|
1990-06-21 |
1991-12-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
|
|
US5198342A
(en)
|
1990-07-05 |
1993-03-30 |
Immunex Corporation |
DNA encoding IgA Fc receptors
|
|
KR930702029A
(ko)
|
1990-08-31 |
1993-09-08 |
스티븐 체스노프 |
동종접합된 면역 글로불린
|
|
GB9022545D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Culture medium
|
|
GB9022543D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
|
GB9105245D0
(en)
|
1991-03-12 |
1991-04-24 |
Lynxvale Ltd |
Binding molecules
|
|
US6797492B2
(en)
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
|
EP0590067A1
(en)
|
1991-06-14 |
1994-04-06 |
Xoma Corporation |
Microbially-produced antibody fragments and their conjugates
|
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
|
US5264586A
(en)
|
1991-07-17 |
1993-11-23 |
The Scripps Research Institute |
Analogs of calicheamicin gamma1I, method of making and using the same
|
|
EP0604580A1
(en)
|
1991-09-19 |
1994-07-06 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
|
|
US5623053A
(en)
|
1992-01-10 |
1997-04-22 |
California Institute Of Technology |
Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5686072A
(en)
*
|
1992-06-17 |
1997-11-11 |
Board Of Regents, The University Of Texas |
Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
|
|
CA2150262C
(en)
|
1992-12-04 |
2008-07-08 |
Kaspar-Philipp Holliger |
Multivalent and multispecific binding proteins, their manufacture and use
|
|
US20030108548A1
(en)
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
GB9316989D0
(en)
|
1993-08-16 |
1993-09-29 |
Lynxvale Ltd |
Binding molecules
|
|
WO1995026403A1
(en)
|
1994-03-29 |
1995-10-05 |
Celltech Therapeutics Limited |
Antibodies against e-selectin
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
PL179659B1
(pl)
|
1994-07-21 |
2000-10-31 |
Akzo Nobel Nv |
Kompozycja cyklicznych nadtlenków ketonów sluzaca do modyfikowania (ko)polimerów zwlaszcza do degradacji polipropylenu PL PL PL PL PL PL PL
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
US6214388B1
(en)
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
DK0805628T3
(da)
|
1995-01-17 |
2003-07-14 |
Brigham & Womens Hospital |
Receptor specifik transepitheltransport af immunogener
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
ES2161290T3
(es)
|
1995-03-30 |
2001-12-01 |
Pfizer |
Derivados de quinazolina.
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
US6444789B1
(en)
|
1995-05-03 |
2002-09-03 |
Applied Research Systems Ars Holding N.V. |
CD16-II variants
|
|
JPH11505704A
(ja)
*
|
1995-05-17 |
1999-05-25 |
リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ |
アンチｃｄ−１９抗体の単鎖可変領域フラグメントを含む免疫コンジュゲート
|
|
US6365161B1
(en)
|
1995-06-07 |
2002-04-02 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-FC receptor binding agents
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
EP0904107B1
(en)
|
1996-03-18 |
2004-10-20 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
US6254868B1
(en)
|
1996-03-20 |
2001-07-03 |
Immunomedics, Inc. |
Glycosylated humanized B-cell specific antibodies
|
|
SI0892789T2
(sl)
|
1996-04-12 |
2010-03-31 |
Warner Lambert Co |
Ireverzibilni inhibitorji tirozin kinaz
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
EP0938506B1
(en)
|
1996-07-16 |
2003-11-05 |
Plückthun, Andreas, Prof. Dr. |
Immunoglobulin superfamily domains and fragments with increased solubility
|
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
AU5927398A
(en)
|
1997-01-21 |
1998-08-07 |
Human Genome Sciences, Inc. |
Fc receptors and polypeptides
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
CA2286262A1
(en)
|
1997-04-11 |
1998-10-22 |
California Institute Of Technology |
Apparatus and method for automated protein design
|
|
EP1255209A3
(en)
|
1997-04-11 |
2009-02-11 |
California Institute Of Technology |
Apparatus and method for automated protein design
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20040191256A1
(en)
|
1997-06-24 |
2004-09-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
US20030105294A1
(en)
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
PT2180007E
(pt)
|
1998-04-20 |
2013-11-25 |
Roche Glycart Ag |
Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
|
PL199747B1
(pl)
|
1998-04-21 |
2008-10-31 |
Micromet Ag |
Jednołańcuchowy wielofunkcyjny polipeptyd, polinukleotyd, wektor, komórka, sposób wytwarzania polipeptydu, kompozycja, zastosowanie polipeptydu lub wektora lub polinukleotydu i zastosowanie polinukleotydu lub wektora oraz sposób identyfikacji aktywatorów lub inhibitorów aktywacji lub stymulacji komórek T
|
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
|
EP1082137A4
(en)
|
1998-05-06 |
2004-05-19 |
Univ Temple |
REVERSE OF PERCENTAL RESPONSE BY INTERRUPTING THE MACROPHAGE RECEPTOR FcSg (g) RI
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US6306926B1
(en)
|
1998-10-07 |
2001-10-23 |
3M Innovative Properties Company |
Radiopaque cationically polymerizable compositions comprising a radiopacifying filler, and method for polymerizing same
|
|
US6403312B1
(en)
|
1998-10-16 |
2002-06-11 |
Xencor |
Protein design automatic for protein libraries
|
|
US20020048772A1
(en)
|
2000-02-10 |
2002-04-25 |
Dahiyat Bassil I. |
Protein design automation for protein libraries
|
|
US20030049654A1
(en)
|
1998-10-16 |
2003-03-13 |
Xencor |
Protein design automation for protein libraries
|
|
AU774334B2
(en)
|
1998-10-16 |
2004-06-24 |
Xencor |
Protein design automation for protein libraries
|
|
US7315786B2
(en)
|
1998-10-16 |
2008-01-01 |
Xencor |
Protein design automation for protein libraries
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR20060067983A
(ko)
|
1999-01-15 |
2006-06-20 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
HUP0201009A2
(en)
|
1999-05-07 |
2002-07-29 |
Genentech Inc |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
AU782160B2
(en)
|
1999-06-09 |
2005-07-07 |
Immunomedics Inc. |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
|
|
US6638515B2
(en)
|
1999-09-07 |
2003-10-28 |
Walter Schubert |
Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V
|
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
|
ES2591102T3
(es)
|
1999-11-29 |
2016-11-24 |
The Trustees Of Columbia University In The City Of New York |
Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
|
|
DE19958134C2
(de)
|
1999-12-02 |
2003-05-15 |
Koenig & Bauer Ag |
Saugwalze
|
|
CA2399561A1
(en)
|
2000-02-03 |
2001-08-09 |
Lennart Hammarstrom |
Ruminant mhc class i-like fc receptors
|
|
WO2001059066A2
(en)
|
2000-02-10 |
2001-08-16 |
Xencor, Inc. |
Protein design automation for protein libraries
|
|
AU4761601A
(en)
|
2000-04-11 |
2001-10-23 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
|
CA2399940A1
(en)
|
2000-04-13 |
2001-10-25 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
|
US6358733B1
(en)
|
2000-05-19 |
2002-03-19 |
Apolife, Inc. |
Expression of heterologous multi-domain proteins in yeast
|
|
AU2001270134B2
(en)
|
2000-06-22 |
2006-06-15 |
University Of Iowa Research Foundation |
Methods for enhancing antibody-induced cell lysis and treating cancer
|
|
AU2001291175A1
(en)
|
2000-09-21 |
2002-04-02 |
Md Online Inc. |
Medical image processing systems
|
|
KR100877676B1
(ko)
|
2000-10-06 |
2009-01-09 |
교와 핫꼬 기린 가부시키가이샤 |
항체 조성물을 생산하는 세포
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
WO2002030954A1
(en)
|
2000-10-06 |
2002-04-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of purifying antibody
|
|
US7465790B2
(en)
|
2000-10-09 |
2008-12-16 |
Isis Innovation, Inc. |
Therapeutic antibodies
|
|
WO2002043658A2
(en)
|
2000-11-06 |
2002-06-06 |
The Jackson Laboratory |
Fcrn-based therapeutics for the treatment of auto-immune disorders
|
|
US7235643B2
(en)
|
2000-11-07 |
2007-06-26 |
Morphotek, Inc. |
Antibodies and methods for generating genetically altered antibodies with high affinity
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
US20040253242A1
(en)
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
|
EP2357187A1
(en)
|
2000-12-12 |
2011-08-17 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
MXPA03005273A
(es)
|
2000-12-14 |
2003-09-25 |
Genentech Inc |
Anticuerpos producidos procarioticamente y sus usos.
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
WO2002061093A1
(en)
|
2001-01-30 |
2002-08-08 |
Degussa Ag |
Nucleotide sequences which code for the otsa gene of c. glutamicum
|
|
CA2436180C
(en)
|
2001-01-31 |
2011-11-08 |
Idec Pharmaceutical Corporation |
Immunoregulatory antibodies and uses thereof
|
|
US20030103971A1
(en)
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
US20040136908A1
(en)
|
2001-04-09 |
2004-07-15 |
Olson William C. |
Anti-cd19 immunotoxins
|
|
CA2448319C
(en)
|
2001-05-31 |
2010-07-27 |
Medarex, Inc. |
Cytotoxins, prodrugs, linkers and stabilizers useful therefor
|
|
GB0118662D0
(en)
|
2001-07-31 |
2001-09-19 |
Univ Southampton |
Binding agents
|
|
NZ603111A
(en)
|
2001-08-03 |
2014-05-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
AU2002326581A1
(en)
|
2001-08-10 |
2003-03-03 |
University Of Virginia Patent Foundation |
Enhancing the efficacy of immunotherapies by supplementing with complement
|
|
WO2003014325A2
(en)
|
2001-08-10 |
2003-02-20 |
Xencor |
Protein design automation for protein libraries
|
|
DE60124912T2
(de)
|
2001-09-14 |
2007-06-14 |
Affimed Therapeutics Ag |
Multimerische, einzelkettige, Tandem-Fv-Antikörper
|
|
EP1443961B1
(en)
|
2001-10-25 |
2009-05-06 |
Genentech, Inc. |
Glycoprotein compositions
|
|
EP1314741B1
(en)
|
2001-11-14 |
2007-03-07 |
Affimed Therapeutics AG |
Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof
|
|
US6911321B2
(en)
|
2001-12-19 |
2005-06-28 |
Genentech, Inc. |
Non-human primate Fc receptors and methods of use
|
|
WO2003068801A2
(en)
|
2002-02-11 |
2003-08-21 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20080260731A1
(en)
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
AU2002316574B2
(en)
|
2002-03-15 |
2008-05-01 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
|
US7317087B2
(en)
|
2002-03-25 |
2008-01-08 |
The Uab Research Foundation |
Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
|
|
US20040259150A1
(en)
|
2002-04-09 |
2004-12-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
|
|
EP1354600A1
(en)
|
2002-04-19 |
2003-10-22 |
Affimed Therapeutics AG |
Antibody combination useful for tumor therapy
|
|
CA2491129A1
(en)
|
2002-07-03 |
2004-01-15 |
Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
|
JP2006500009A
(ja)
|
2002-07-09 |
2006-01-05 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
|
DK1534335T4
(en)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
WO2004022717A2
(en)
|
2002-09-05 |
2004-03-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
|
|
CA2499075A1
(en)
|
2002-09-16 |
2004-03-25 |
Elusys Therapeutics, Inc. |
Production of bispecific molecules using polyethylene glycol linkers
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
CA2502904C
(en)
|
2002-10-15 |
2013-05-28 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
RS20100366A
(sr)
|
2002-12-16 |
2011-04-30 |
Genentech, Inc. |
Varijante imunoglobulina i njihova upotreba
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
|
ES2349779T5
(es)
|
2003-04-04 |
2013-11-26 |
Genentech, Inc. |
Formulaciones de anticuerpos y de proteínas a concentración elevada
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
NZ543498A
(en)
|
2003-05-14 |
2007-06-29 |
Immunogen Inc |
A conjugate comprising an antibody chemically coupled to a maytansinoid
|
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
|
WO2005007809A2
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
|
JP2008501621A
(ja)
|
2003-05-31 |
2008-01-24 |
マイクロメット アクツィエン ゲゼルシャフト |
Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
|
|
CN1802167A
(zh)
|
2003-06-12 |
2006-07-12 |
伊莱利利公司 |
融合蛋白质
|
|
US20050163782A1
(en)
|
2003-06-27 |
2005-07-28 |
Biogen Idec Ma Inc. |
Modified binding molecules comprising connecting peptides
|
|
CA2531482A1
(en)
|
2003-06-30 |
2005-01-20 |
Centocor, Inc. |
Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
|
|
BRPI0412890B8
(pt)
|
2003-07-24 |
2021-05-25 |
Innate Pharma |
método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno
|
|
CA2533593A1
(en)
|
2003-07-26 |
2005-02-10 |
Biogen Idec Ma Inc. |
Altered antibodies having improved antigen-binding affinity
|
|
JP4733635B2
(ja)
|
2003-07-31 |
2011-07-27 |
イミューノメディクス、インコーポレイテッド |
抗ｃｄ１９抗体
|
|
WO2005012877A2
(en)
|
2003-08-01 |
2005-02-10 |
Dna Twopointo Inc. |
Systems and methods for antibody engineering
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
JP2007504245A
(ja)
|
2003-09-05 |
2007-03-01 |
ジェネンテック・インコーポレーテッド |
変更したエフェクター機能を有する抗体
|
|
EP1667702A2
(en)
|
2003-09-10 |
2006-06-14 |
Baxter International Inc., Baxter Healthcare Corp. |
Peptides that inhibit complement activation
|
|
WO2005037867A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
EP1697415A1
(en)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
SI1691833T1
(sl)
|
2003-11-28 |
2010-06-30 |
Micromet Ag |
Zmes s polipeptidi
|
|
EP1706424B1
(en)
|
2004-01-12 |
2009-07-22 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
KR100545720B1
(ko)
|
2004-05-31 |
2006-01-24 |
메덱스젠 주식회사 |
당화된 면역글로불린 및 이를 포함하는 면역접합체
|
|
CN101721701A
(zh)
|
2004-07-23 |
2010-06-09 |
健泰科生物技术公司 |
抗体或其片段的结晶
|
|
WO2006047350A2
(en)
*
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
CN105535967B
(zh)
|
2005-02-15 |
2022-05-03 |
杜克大学 |
抗cd19抗体及其在肿瘤学中的应用
|
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
|
JP2008546647A
(ja)
|
2005-06-08 |
2008-12-25 |
デューク ユニバーシティ |
移植のための抗−ｃｄ１９抗体治療
|
|
MX2007015944A
(es)
|
2005-06-20 |
2008-03-07 |
Medarex Inc |
Anticuerpos cd19 y sus usos.
|
|
ES2532124T3
(es)
|
2005-12-16 |
2015-03-24 |
Amgen Research (Munich) Gmbh |
Medios y procedimientos para el tratamiento de enfermedades tumorales
|
|
CN101351477B
(zh)
|
2005-12-30 |
2011-11-16 |
默克专利有限公司 |
具有降低的免疫原性的抗cd19抗体
|
|
US20070166306A1
(en)
|
2006-01-17 |
2007-07-19 |
Fey Georg H M |
Anti-CD19 antibody composition and method
|
|
US20070178103A1
(en)
|
2006-01-30 |
2007-08-02 |
Fey Georg H |
CD19-specific immunotoxin and treatment method
|
|
ME01786B
(me)
|
2006-08-14 |
2014-09-20 |
Xencor Inc |
Optimizovana antitela usmerena na cd19
|
|
AU2007294575B2
(en)
|
2006-09-08 |
2013-06-27 |
Viela Bio, Inc. |
Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
US20080267977A1
(en)
|
2007-04-26 |
2008-10-30 |
Friedrich-Alexander University Of Erlangen-Nuremberg |
Combined immunological agent and sensitizing agent for the treatment of cancer
|
|
DK2176298T3
(en)
*
|
2007-05-30 |
2018-02-12 |
Xencor Inc |
Methods and compositions for inhibiting CD32B-expressing cells
|
|
US9098105B2
(en)
|
2012-08-24 |
2015-08-04 |
Avago Technologies General Ip (Singapore) Pte. Ltd. |
Dynamic Y-buffer size adjustment for retained sector reprocessing
|
|
US9679104B2
(en)
|
2013-01-17 |
2017-06-13 |
Edico Genome, Corp. |
Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform
|
|
US9703321B2
(en)
|
2013-07-09 |
2017-07-11 |
I-Blades, Inc. |
Snap on wearable module
|
|
US9209965B2
(en)
|
2014-01-14 |
2015-12-08 |
Microsemi Semiconductor Ulc |
Network interface with clock recovery module on line card
|
|
US11392902B2
(en)
|
2017-06-06 |
2022-07-19 |
United Parcel Service Of America, Inc. |
Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery
|
|
KR102185854B1
(ko)
|
2017-09-09 |
2020-12-02 |
애플 인크. |
생체측정 인증의 구현
|